Business Wire

All Seas Capital Closes Maiden Fund With US$400m AUM

Share

All Seas Capital, a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, is pleased to announce the final close of its maiden fund, All Seas Capital I SCSp (the “Fund”), with total commitments of US$400m including coinvestments.

All Seas Capital’s global investor base, consisting of pension funds, sovereign wealth funds, consultants, insurance companies and banks from the US, Europe and Asia, provide a well-diversified mix of investors. Since inception to the Fund’s final close, All Seas Capital invested over US$200 million in portfolio companies, including Attivo Group (UK), Hakim Group (UK), SoMeD Santé (France) and Zimmer MedizinSysteme (Germany).

All Seas Capital provides flexible long-term financing solutions to leading Western European mid-market businesses. Alongside transformational capital solutions, the All Seas team provides board level expertise to entrepreneurs and management teams who do not want to sell majority stakes.

ESG considerations are integrated throughout the investment process to help position All Seas Capital’s portfolio for long term, sustained growth and its hybrid strategy, investing a combination of debt and equity, gives investors access to equity-like returns with debt-like structural protections.

All Seas Capital is led by Marc Ciancimino and Cristobal Cuart who co-founded and led KKR's European mezzanine and preferred equity business and have an extensive career track record, with €3.4bn invested across 45 businesses prior to founding All Seas Capital.

Marc Ciancimino, Co-Founder of All Seas Capital, said:

“We would like to take this opportunity to thank our group of investors in All Seas Capital I. The quality and international diversity of our LPs is a great testimony to the investment mandate we are pursuing and we look forward to partnering with them for many years. At All Seas, we identify successful businesses that have already proven their business model but are in need of support and capital as the catalyst for real business growth. Our bespoke form of capital is attractive to management teams, and we are finding no let-up in demand having already backed five fantastic businesses.”

Cristobal Cuart, Co-Founder of All Seas Capital, commented:

“As entrepreneurs ourselves, we launched All Seas Capital to take advantage of the deep pool of opportunities across the European mid-market, accessible through our established sourcing network across our target markets of Western and Northern Europe. We have built a strong and ambitious investment and operational team, with an entrepreneurial culture at its core.”

Gemma Braithwaite, Investor Relations Managing Director of All Seas Capital, commented:

“It’s been an interesting time to be a first time fund, and I am thrilled with the outcome. The whole team has worked hard on the fundraise and that’s reflected in the results. I am especially pleased with the quality of investors we now have alongside us as we grow – a great testament to the differentiated strategy, quality of the team and the growing portfolio.”

All Seas Capital was advised by Debevoise & Plimpton LLP in London. The Luxembourg team consists of Loyens & Loeff, One Fund Management S.A. and Alter Domus.

-Ends-

About All Seas Capital

All Seas Capital is a pan-European private capital fund that provides flexible long-term financing solutions to leading mid cap companies. The team is led by Marc Ciancimino and Cristobal Cuart who co-founded and led KKR's European mezzanine and preferred equity business, and have an extensive career track record with €3.4bn invested across 45 businesses prior to founding All Seas Capital.

We partner with and provide transformational capital solutions and board level expertise to Western European entrepreneur- and family-owned mid-market businesses who need strategic capital, but do not want to sell majority stakes. We identify businesses that already have a certain amount of scale but are in need of support and capital as the catalyst for real business growth.

All Seas Capital’s hybrid strategy, investing a combination of debt and equity, integrates ESG considerations throughout its investment process to help position its portfolio for long term, sustained growth.

www.allseascapital.com

Marc Ciancimino, Co-Founder

Prior to starting All Seas, Marc was a partner (“Member”) of KKR & Co where he spent a decade and started the European dimension of the firm’s private credit activities with a special emphasis on hybrid transactions. He sat on the Global Private Credit Committee and was a Portfolio Management Committee member. He started his career in 1995 at Citibank and also worked at Bankers Trust before moving to the buyside in 1999. He has invested over $1.9bn since he started his career.

Cristobal Cuart, Co-Founder

Prior to All Seas, Cristobal was a Director at KKR which he joined in 2010 where he was a senior member of the European private credit and preferred equity platform, working closely with Marc Ciancimino to launch and grow the firm’s European private credit and preferred equity activities. He has invested over $2.2bn into privately held businesses throughout his career.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:

All Seas Capital
Charlotte Balbirnie
+44 7989 528421
CBalbirnie@keplercomms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye